science bio retatrutide | Research Grade Peptide Retatrutide Explained: The Triple Agonist

In one phase 2 study: Pancreatitis was reported in about 0.4% of participants (1 out of 267) Gallbladder issues affected roughly 1.1%, with no cases in the placebo group Heart rhythm changes were reported more often in people taking retatrutide (about 6% compared to 3% with placebo) Liver enzyme increases were rare (around 1%), and overall liver health markers stayed stable over time

Each consultation covers full medical history, potential contraindications, and metabolic screening before any prescription is written

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, which typically diminish over time

Journal of Medical Internet Research, 26, e65440